Korea United Pharm
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Korea United Pharm makes prescription medicines, including drugs for circulation, digestion, and other conditions, that are supplied to patients through hospitals and pharmacies in Korea and exported to dozens of countries worldwide.
Listed on KOSPI, Korea's main stock exchange, the company focuses on 'improved new drugs' (reformulated or enhanced versions of existing medicines that offer better delivery or efficacy). Its single most defining structural fact is that it consistently reinvests a high share of revenue back into research and development, and has launched nearly two dozen improved or newly formulated drug products to date.
Summary is AI-generated and may contain errors · figures from DART filings
The South Korean government has formally designated the company as an 'innovative pharmaceutical enterprise,' a national recognition that reflects its R&D-focused business model.
Korea United Pharm in five facts
What does Korea United Pharm do?
Korea United Pharm makes prescription medicines, including drugs for circulation, digestion, and other conditions, that are supplied to patients through hospitals and pharmacies in Korea and exported to dozens of countries worldwide.
Where is Korea United Pharm listed and in which sector?
Korea United Pharm (Korean name: 유나이티드제약) trades under KRX code 033270 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is Korea United Pharm?
Its market capitalisation was US$209.3M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Korea United Pharm's latest annual revenue and operating profit?
For fiscal year 2025, Korea United Pharm reported revenue of US$217.9M, operating profit of US$37.4M and net income of US$28.9M, per its annual report on DART (data retrieved from DART on 2026-09-08). Revenue was up 0.0% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-08
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Change of largest shareholder
Korea United Pharm's largest-shareholder group changed from Kang Deok-young and 15 others to Kang Won-ho and 15 others (unchanged at 6,617,910 shares, 41.59%), following a gift of 800,000 shares from Kang Deok-young to his son Kang Won-ho effective 2026-08-11.
Ownership change · Aug 11 - Operating results (preliminary) (fair disclosure)
Korea United Pharm filed provisional (unaudited) separate results for Q2 2026: revenue of US$54.4M (+9.7% year on year), operating profit of US$9.36M (+23.6% year on year) and net income of US$26.5M (+3094.2% year on year).
Earnings · Jul 30 - Operating results (preliminary) (fair disclosure)
Korea United Pharm filed provisional (unaudited) separate results for Q1 2026: revenue of US$50.1M (+3.5% year on year), operating profit of US$7.64M (−18.3% year on year) and net income of US$9.49M (+10.5% year on year).
Earnings · Apr 30 - Cash/in-kind dividend decision
Korea United Pharm declared a cash dividend of US$0.43 per share.
Dividend · Feb 27 - [Amended] Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Korea United Pharm updated its previously filed separate results for FY2025: revenue of US$202M (0% year on year), operating profit of US$34.7M (−11.9% year on year) and net income of US$26.8M (+18% year on year).
Earnings · Feb 26 · 2 versions